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Identiﬁ cation of additional risk loci for stroke and small 
vessel disease: a meta-analysis of genome-wide association 
studies 
Neurology Working Group of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, the Stroke Genetics 
Network (SiGN), and the  International Stroke Genetics Consortium (ISGC)*
Summary 
Background Genetic determinants of stroke, the leading neurological cause of death and disability, are poorly 
understood and have seldom been explored in the general population. Our aim was to identify additional loci for 
stroke by doing a meta-analysis of genome-wide association studies. 
Methods For the discovery sample, we did a genome-wide analysis of common genetic variants associated with incident 
stroke risk in 18 population-based cohorts comprising 84 961 participants, of whom 4348 had stroke. Stroke diagnosis 
was ascertained and validated by the study investigators. Mean age at stroke ranged from 45·8 years to 76·4 years, and 
data collection in the studies took place between 1948 and 2013. We did validation analyses for variants yielding a 
signiﬁ cant association (at p<5 × 10–⁶) with all-stroke, ischaemic stroke, cardioembolic ischaemic stroke, or non-
cardioembolic ischaemic stroke in the largest available cross-sectional studies (70 804 participants, of whom 19 816 had 
stroke). Summary-level results of discovery and follow-up stages were combined using inverse-variance weighted ﬁ xed-
eﬀ ects meta-analysis, and in-silico lookups were done in stroke subtypes. For genome-wide signiﬁ cant ﬁ ndings (at 
p<5 × 10–⁸), we explored associations with additional cerebrovascular phenotypes and did functional experiments using 
conditional (inducible) deletion of the probable causal gene in mice. We also studied the expression of orthologs of this 
probable causal gene and its eﬀ ects on cerebral vasculature in zebraﬁ sh mutants.
Findings We replicated seven of eight known loci associated with risk for ischaemic stroke, and identiﬁ ed a novel locus at 
chromosome 6p25 (rs12204590, near FOXF2) associated with risk of all-stroke (odds ratio [OR] 1·08, 95% CI 1·05–1·12, 
p=1·48 × 10–⁸; minor allele frequency 21%). The rs12204590 stroke risk allele was also associated with increased MRI-
deﬁ ned burden of white matter hyperintensity—a marker of cerebral small vessel disease—in stroke-free adults 
(n=21 079; p=0·0025). Consistently, young patients (aged 2–32 years) with segmental deletions of FOXF2 showed an 
extensive burden of white matter hyperintensity. Deletion of Foxf2 in adult mice resulted in cerebral infarction, reactive 
gliosis, and microhaemorrhage. The orthologs of FOXF2 in zebraﬁ sh (foxf2b and foxf2a) are expressed in brain pericytes 
and mutant foxf2b–/– cerebral vessels show decreased smooth muscle cell and pericyte coverage. 
Interpretation We identiﬁ ed common variants near FOXF2 that are associated with increased stroke susceptibility. 
Epidemiological and experimental data suggest that FOXF2 mediates this association, potentially via diﬀ erentiation 
defects of cerebral vascular mural cells. Further expression studies in appropriate human tissues, and further 
functional experiments with long follow-up periods are needed to fully understand the underlying mechanisms.
Funding NIH, NINDS, NHMRC, CIHR, European national research institutions, Fondation Leducq. 
Introduction
Stroke is the leading neurological cause of death and 
disability worldwide.1 A substantial proportion of stroke 
risk remains unexplained, and contribution of genetic 
factors is supported by discoveries of common genetic 
variation associated with stroke risk, identiﬁ ed through 
large, collaborative, genome-wide association studies 
(GWAS).2 These studies have estimated the proportion of 
phenotype variance explained by the genome-wide 
genotypes to range between 16% and 40% for ischaemic 
stroke, and between 34% and 73% for intracerebral 
haemorrhage.3 Most associations so far have been speciﬁ c 
to particular ischaemic or haemorrhagic stroke types, 
although a few risk loci for overall ischaemic stroke have 
also been reported.2 Overall, the search for stroke loci has 
been less successful than for other complex phenotypes.4 
Potential explanations include heterogeneity of stroke and 
limited ability to detect genetic variants increasing both 
stroke risk and severity because of the cross-sectional 
design of most studies, with hospital-based case 
ascertainment and non-inclusion of severe strokes with 
early mortality. Population-based cohort studies, with blood 
samples drawn at recruitment and prospective incident 
stroke ascertainment oﬀ er the advantage of including 
participants with severe strokes leading to early death. 
We did a genome-wide analysis for common genetic 
variants associated with an increased risk of incident 
stroke in population-based cohort studies and validated 
these results with analysis of association between the 
identiﬁ ed variants and stroke in the largest available 
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cross-sectional studies. Detailed functional exploration of 
novel genome-wide signiﬁ cant association was done in 
zebraﬁ sh and mice.
Methods 
Study population for discovery analysis 
The GWAS discovery sample comprised 84 961 participants 
of European origin from 18 community-based prospective 
cohort studies participating in the Cohorts of Heart and 
Aging Research in Genomic Epidemiology (CHARGE) 
consortium. All participants did not have stroke at baseline 
and 4348 developed incident stroke during an average of 
10 years (SD 3·6) of follow-up (table 1, appendix pp 8–13). 
Some, but not all, of the cohorts included in our analysis 
(representing <1544 incident stroke cases) have been 
included in published HapMap-based stroke GWAS.5,6 
This study was approved by the ethics committees of the 
participating studies and written informed consent was 
obtained from all study participants in the original cohort 
studies that allowed for data use in subsequent studies.
Stroke deﬁ nition and classiﬁ cation of subtypes 
Stroke was deﬁ ned as a focal neurological deﬁ cit of 
presumed vascular origin with sudden onset and 
lasting for at least 24 hours, or until death if the 
participant died less than 24 hours after onset of 
symptoms. Stroke diagnosis and classiﬁ cation was 
validated by an expert committee in participating 
studies (appendix pp 13–19). Strokes were classiﬁ ed as 
ischaemic stroke (n=3028), intracerebral haemorrhage 
(n=277), or unknown type based on clinical and 
imaging criteria; for cohorts in which ischaemic stroke 
subtypes were available (table 1), ischaemic stroke was 
subdivided into cardio embolic (n=602) and non-
cardioembolic (n=1770) subtypes. Numbers of events 
were too small to analyse large-vessel ischaemic stroke 
(n=117) and small-vessel ischaemic stroke (n=87) 
separately in this discovery dataset. Subarachnoid 
haemorrhage was not analysed because of its distinct 
mechanisms and very small number of events. Detailed 
deﬁ nitions of stroke types and subtypes are given in 
the appendix. 
Genotyping and imputation 
Genotyping platforms and quality control ﬁ lters are 
described in the appendix (pp 42–43). All but one study 
used imputed genotypes based on the 1000GpIv3 “All” 
reference panel (appendix pp 44–45). 
For details of participating 
studies see http://www.
chargeconsortium.com/ and 
http://strokegenetics.org/
Research in context 
Evidence before this study
We searched PubMed with the search terms “stroke”, “cerebral 
small vessel disease”, “genetics”, “GWAS”, ”genomics”, and the 
GWAS catalogue for reports before June, 2015, with no 
language restrictions; we only included peer-reviewed reports 
in English. Most of the seven studies found only associations 
with cardioembolic or large-vessel ischaemic stroke, and no 
robust genetic association has been reported for other 
subtypes, especially the very common but poorly understood 
small-vessel ischaemic stroke. Genetic associations with 
overall stroke were also scarcely reported, with only a few 
genetic studies thoroughly investigating incident stroke in a 
population-based longitudinal setting. Although genome-
wide association studies (GWAS) have successfully identiﬁ ed 
numerous genetic associations with complex diseases, 
including stroke, biological mechanisms underlying these 
associations are unknown for most of the variants, precluding 
clinical applications beyond risk prediction.  
Added value of this study 
First, discovery analyses were done in 4348 cases and 
80 613 controls and ﬁ ndings were validated in an additional 
19 816 cases and 50 988 controls. We identiﬁ ed a novel risk 
locus for stroke that appears to be mediated by small vessel 
disease. Although small vessel disease is one of the major 
subtypes of stroke, GWAS have so far not discovered risk loci for 
small-vessel ischaemic stroke (except for an association with the 
PRKCH locus identiﬁ ed in a study in Japanese participants, which 
was not found in European populations). Second, we provide 
preliminary experimental evidence from zebraﬁ sh and mouse 
models that the recorded statistical association reﬂ ects an eﬀ ect 
of the nearby transcription factor FOXF2 (a gene predominantly 
expressed in fetal tissue) on the development of cerebral 
vasculature. Conditional deletion of Foxf2 in adult mice led to 
cerebral infarction, reactive gliosis, and microhaemorrhage. In 
zebraﬁ sh, foxf2b–/– mutants showed decreased smooth-muscle 
cell and pericyte coverage. Third, we show that patients with a 
rare monogenic ophthalmological condition due to segmental 
deletions encompassing FOXF2 also exhibit features of cerebral 
small vessel disease, providing an example of how monogenic 
conditions can inform the mechanisms of complex diseases. 
Implications of all the available evidence
The present ﬁ ndings provide insight into the genetic 
underpinnings of stroke, especially of the small vessel 
subtype, with evidence from multiple approaches for a pivotal 
role of FOXF2, a neural crest expressed transcription factor 
involved in cerebral vessel development. Cerebral small vessel 
disease is a major, but poorly understood, cause of stroke in 
all ethnic groups, and subclinical small vessel disease (which 
was also associated with the stroke risk variants near FOXF2 in 
our study) has been associated with progressive functional 
and cognitive decline, and increased risk of dementia. At 
present, no mechanism-based treatment is available for small 
vessel disease, other than management of risk factors. Our 
ﬁ ndings indicate a possible novel mechanism of stroke and 
small vessel disease. Further research is warranted to explore 
whether these ﬁ ndings can be applied to clinical practice. 
See Online for appendix
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Genome-wide association analyses 
Using genome-wide multivariable Cox regression, we 
tested associations of genetic variants with incident stroke 
(all stroke, ischaemic stroke, cardioembolic ischaemic 
stroke, non-cardioembolic ischaemic stroke, and in 
secondary analyses intracerebral haemorrhage) under an 
additive genetic model, adjusting for sex and age and, 
when relevant, for principal components of population 
stratiﬁ cation, study site, or familial structure (appendix pp 
19, 20, 46). Meta-analysis of study-speciﬁ c association 
statistics was done by GC and AYC at two sites (University 
of Bordeaux, Bordeaux, France, and Harvard Medical 
School, Boston, MA, USA) with inverse-variance weighted 
meta-analysis with METAL (A software designed to 
facilitate meta-analysis of large datasets). The quantile–
quantile plots and values of the genomic inﬂ ation factor λ 
suggested no systematic inﬂ ation of test statistics due to 
population stratiﬁ cation, cryptic relatedness, or technical 
arteﬁ cts (appendix pp 33, 47). Power of the discovery stage 
to detect association with various stroke subtypes is 
presented in the appendix (p 34).
Validation analyses 
We selected variants with high imputation accuracy 
(mean r²>0·80) yielding an association at p<5 × 10–⁶ 
signiﬁ cance level with all stroke, ischaemic stroke, 
cardioembolic ischaemic stroke, or non-cardioembolic 
ischaemic stroke. 177 variants belonging to 21 loci (linkage 
disequilibrium r²>0·7 within each locus) were selected. 
We did in-silico lookups of association results using data 
from four independent, previously published cross-
sectional studies, with mostly hospital-based stroke 
ascertainment, totalling 19 816 stroke patients (table 1) 
and 50 988 control participants from the Stroke Genetics 
Country Total (n) All stroke (n) Ischaemic 
stroke (n)
Cardioembolic-
ischaemic stroke 
(n)
Non-
cardioembolic 
ischaemic 
stroke (n)*
Women (%)† Age at stroke 
(years)
Age of controls
at DNA draw 
(years)
Follow-up 
(years)
Discovery sample (longitudinal population-based cohort studies)
AGES USA 2996 114 99 NA NA 58% 79·9 (5·5) 76·4 (5·5) 3·6 (1·1)
ARIC USA 8939 473 416 108 305 53% 69·3 (7·4) 54·2 (5·7) 19·1 (4·6)
CHS USA 3268 563 447 139 308 61% 82·7 (6·2) 72·3 (5·4) 13·5 (6·3)
FHS USA 4369 235 198 57 127 55% 73·4 (11·7) 65·5 (12·7) 8·0 (3·2)
FINRISK CoreExome Finland 5202 94 60 NA NA 55% 69·9 (9·4) 45·8 (12·8) 13·3 (2·7)
FINRISK Corogene Finland 1887 60 46 NA NA 49% 73·7 (9·5) 55·2 (12·2) 9·0 (4·0)
FINRISK Predict CVD Finland 1309 352 294 NA. NA 53% 66·5 (9·8) 46·5 (13·3) 10·0 (5·2)
Health ABC USA 1661 124 NA NA NA 47% 80·1 (4·2) 73·8 (2·8) 9·3 (2·9)
MESA USA 2364 49 43 NA 35 52% 75·1 (8·9) 62·7 (10·2) 7·2 (1·4)
PROSPER Netherlands 4658 193 NA NA NA 53% 77·8 (3·6) 75·2 (3·3) 3·1 (0·7)
Rotterdam Study I Netherlands 6066 821 448 95 353 60% 80·6 (8·1) 69·2 (9·0) 13·0 (6·2)
Rotterdam Study II Netherlands 2080 125 88 17 71 54% 75·9 (9·2) 64·6 (7·9) 9·7 (2·5)
SHIP Germany 3112 75 37 NA NA 52% 71·8 (10·6) 48·7 (15·2) 12·1 (2·5)
TWINGENE Sweden 6702 116 95 NA NA 52% 75·6 (8·8) 64·9 (8·1) 3·2 (1·0)
ULSAM Sweden 1139 216 171 56 115 0% 79·9 (4·8) 71·0 (0·6) 12·8 (5·2)
WGHS USA 23 294 499 402 82 320 100% 69·6 (9·3) 54·7 (7·1) 16·0 (3·2)
3C Study Dijon France 3762 157 125 33 92 62% 81·5 (6·1) 72·4 (5·6) 8·7 (3·1)
3C Study Bordeaux 
and Montpellier
France 2153 82 59 15 44 60% 81·7 (5·2) 73·9 (5·1) 7·8 (2·5)
Total 84 961 4348 3028 602 1770 67% 75·8 (8·0) 63·7 (8·4) 10·0 (3·6)
Validation sample (cross-sectional case-control studies)*
SiGN USA and 
Europe
49 324 16 851 16 851 3427 2346/3150‡ 46% 66·5 (14·8) NA‡ NA
METASTROKE USA and 
Europe
9654 1729 1729 276 206/159‡ 36% 67·0 (10·1) 60·6 (11·9) NA
HVH1 USA 2012 681 577 92 62/175‡ 57% 68·8 (8·9) 66·7 (9·1) NA
CADISP Europe 9814 555 555 211 67/31‡ 61% 43·7 (9·9) NA‡ NA
Total 70 804 19 816 19 712 4006 2681/3515‡ 47% NA NA NA
Data are mean (SD) or n (%). NA=not available. AGES=Age, Gene/Environment Susceptibility-Reykjavik Study. ARIC=Atherosclerosis Risk in Communities Study.  CHS=Cardiovascular Health Study.  
FHS=Framingham Heart Study.  ABC=Health, Aging, and Body Composition.  MESA=Multi-Ethnic Study of Atherosclerosis.  PROSPER=Prospective Study of Pravastatin in the Elderly at Risk.  SHIP=Study of Health 
In Pomerania.  ULSAM=Uppsala Longitudinal Study of Adult Men.  WGHS=Women’s Genome Health Study.  SiGN=Stroke Genetics Network.  HVH1= Heart and Vascular Health. CADISP=Cervical Artery 
Dissections and Ischemic Stroke Patients. *More detailed descriptions of composition of replication studies are shown in the appendix. †Percentage of women calculated from the total (n) column. ‡Samples are 
from large-vessel ischaemic stroke or small-vessel ischaemic stroke. §Mean age of controls in SiGN and CADISP study is not available because they were obtained from anonymous genotype databases. 
Table 1: Population characteristics
For more on METAL see http://
csg.sph.umich.edu/abecasis/
Metal/
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Network (SiGN),7,8 METASTROKE,6 Heart and Vascular 
Health 1 (HVH1),9 and Cervical Artery Dissections and 
Ischaemic Stroke Patients (CADISP) studies.10 Except for 
4963 black and 3371 Hispanic participants (cases and 
controls) in SiGN, participants in the validation samples 
were of European ancestry. Validation analyses were done 
with the same, or most similar, stroke phenotype as in the 
discovery phase (table 1), with logistic regression under 
an additive genetic model, followed by inverse-variance 
weighted meta-analysis of study-speciﬁ c association 
statistics (appendix pp 20–25). 
After Bonferroni correction for the number of 
independent loci (r²<0·01 reﬂ ecting absence of linkage 
disequilibrium), p<2·38 × 10–³ was considered signiﬁ cant 
evidence of replication. We did not correct for the 
number of stroke phenotypes (all stroke, ischaemic 
stroke, cardioembolic ischaemic stroke, and non-
cardioembolic ischaemic stroke) because they are not 
independent (cardioembolic and non-cardioembolic 
ischaemic stroke being subtypes of ischaemic stroke, and 
ischaemic stroke a subtype of stroke). Only loci reaching 
genome-wide signiﬁ cance at p<5 × 10–⁸ in the combined 
meta-analysis of discovery and validation samples were 
given further consideration.
Secondary analyses 
We examined the association of novel, genome-wide 
signiﬁ cant (at p<5×10-8), all-stroke risk variants with stroke 
subtypes in CHARGE and follow-up samples (using 
TOAST subtyping11 and, in sensitivity analyses, the 
Causative Classiﬁ cation System [CCS] implemented in 
SiGN7,8). We examined whether the same variants were 
associated with burden of white matter hyperintensity, a 
quantitative MRI-marker of cerebral small vessel disease, 
in 21 079 participants,12 and with intracerebral 
haemorrhage in an independent study comprising 
1576 patients (682 patients with lobar intracerebral 
haemorrhage and 894 with deep intracerebral 
haemorrhage) and 1303 controls of European ancestry.13 
We tested whether risk variants with genome-wide or 
suggestive association for all-stroke or ischaemic stroke in 
the population-based discovery stage were associated with 
incident fatal and non-fatal stroke. We also looked for a 
signiﬁ cant association of these risk variants comparing 
fatal or non-fatal stroke, which would suggest diﬀ erent 
genetic inﬂ uences in the two groups of cases, assuming 
systematic bias in follow-up does not inﬂ uence the 
frequency of the candidate variant in either group.
Functional exploration of novel stroke risk locus
Based on in-silico functional annotation (appendix 
pp 29–31) and literature review of the novel genome-
wide signiﬁ cant stroke risk locus identiﬁ ed by the 
aforementioned approach, we examined the eﬀ ect of 
loss of function of the putative causal gene on brain 
vasculature and stroke-related phenotypes in humans, 
mice, and zebraﬁ sh (appendix pp 31, 32). Studies into 
human participants and animal models were approved 
by the ethics committees of the participating 
institutions. To complement the genome-wide analysis, 
we used a rare cohort of patients with Axenfeld-Rieger 
syndrome with deletions of the novel stroke risk locus 
to directly determine if loss of this locus resulted in 
more severe cerebrovascular MRI phenotypes. By 
extracting data from individual MRI slices, we calculated 
the volume of white matter hyperintensity in two 
patients (aged 2 and 32 years) with large segmental 
deletions encompassing the putative causal gene  and 
two patients (aged 15 and 17 years) with smaller 
deletions in whom this gene was intact.
The putative causal gene was deleted in adult (12 weeks) 
conditional (inducible) mouse mutants by Cre-ERT2, an 
inducible Cre recombinase14 and killed 6 weeks later. 
Brains of conditional knockout mice and controls were 
examined by histology (using haematoxylin and eosin or 
Richardson’s methylene blue–Azure 2 staining) and 
glial ﬁ brillary acidic protein immuno ﬂ uorescence 
(DAKO Z0334) to search for features of vascular brain 
injury. 
Zebraﬁ sh allow live imaging of blood vessel and mural 
cell interactions to be done with exceptional clarity, 
using transgenic lines that permit in-vivo visualisation 
of endothelium and smooth muscle. Expression of the 
putative causal gene in the brain of zebraﬁ sh larvae was 
assessed by in-situ hybridisation and compared with 
that of established pericyte markers notch3 and pdgfrβ.15 
Function of forkhead transcription factor 2 (Foxf2) was 
assessed by knockout with transcription activator-like 
eﬀ ector nucleases (TALENs) to create targeted nonsense 
mutations in the DNA-binding domain (appendix p 35). 
Smooth muscle cell coverage of branches of brain 
vessels was examined in live transgenic mutant and 
wild-type zebraﬁ sh embryos; these smooth muscle cells 
in zebraﬁ sh were modiﬁ ed to express green ﬂ uorescent 
protein with the α-smooth muscle actin promoter 
(acta2:GFP) at 4–6 days postfertilisation. Pericyte 
density was assessed by pdgfrβ in-situ hybridisation.15
Role of the funding source 
All funders were involved in the study design but had no 
role in data collection. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Results 
In the population-based discovery stage (4348 stroke 
patients vs 80 613 controls), 177 genetic variants in 
21 independent loci were associated with incident 
all-stroke, ischaemic stroke, cardioembolic ischaemic 
stroke, or non-cardioembolic ischaemic stroke at 
p<5 × 10–⁶ signiﬁ cance (appendix pp 48–54). 11 loci 
showed suggestive association with incident all-stroke 
or ischaemic stroke at p<5 × 10–⁶. Ten additional loci 
were associated with incident cardioembolic ischaemic 
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stroke at p<5 × 10–⁶ signiﬁ cance, with one locus (the 
lead single nucleotide polymorphism [SNP] rs72794386 
in SLC12A2) showing genome-wide signiﬁ cance 
(hazard ratio [HR] 1·67, 95% CI 1·39–2·00, 
p=4·37 × 10–⁸) and minor allele frequency (MAF) of 10% 
(table 2, appendix pp 36, 37) 
Chromosome: 
position*
Function Gene Number 
of 
variants†
Minor 
allele
Minor 
allele 
frequency
Hazard ratio 
(95% CI)
p value‡ Direction§ Heterogeneity, 
I2¶
Heterogeneity, 
p value||
Imputation 
quality**
All stroke
rs6433905 2:182138150 Intergenic UBE2E3 2 C 0·08 1·21
(1·12–1·31)
2·54 × 10–6 +++++++++++++++ 0 0·54 0·97
rs12204590 6:1337393 Intergenic FOXF2 6 A 0·21 1·14
(1·08–1·20)
2·17 × 10–6 ++++++++++++-+-++ 0 0·60 1·00
rs790919 6:154298875 Intergenic OPRM1 2 A 0·44 1·12
(1·07–1·17)
2·44 × 10–6 +++++++++++++--++ 16·2 0·26 0·96
rs11788316 9:13445687 Intergenic MPDZ 4 T 0·28 1·13
(1·07–1·19)
2·49 × 10–6 ++-++++--++++++--+ 0 0·84 0·96
rs11627959 14:35160471 Intergenic CFL2 4 A 0·44 0·89
(0·85–0·93)
2·23 × 10–6 --+------+--+---- 0 0·87 0·93
rs4899120 14:64335447 Intronic SYNE2 1 T 0·09 1·19
(1·11–1·29)
4·71 × 10–6 +++-++++++++--++ 24 0·18 0·98
Ischaemic stroke
rs62262077 3:105014929 Intergenic ALCAM 5 A 0·27 1·17
(1·10–1·24)
6·04 × 10–7 -+++++++++++-+++ 19·2 0·23 0·94
rs10037362 5:31110857 Intergenic CDH6 2 A 0·07 1·27
(1·15–1·40)
4·41 × 10–6 -+-++++++++ 25·7 0·20 0·97
rs4448595 10:21666138 Intergenic C10orf114 8 G 0·16 0·83
(0·77–0·90)
2·50 × 10–6 --------+------- 0 0·80 0·98
rs11833579 12:775199 Intergenic NINJ2 2 A 0·24 1·19
(1·12–1·27)
5·74 × 10–8 -+++-++++++-++++ 18·5 0·24 0·92
rs77858481 13:81142325 Intergenic SPRY2 1 G 0·06 1·38
(1·22–1·55)
2·32 × 10–7 ++++++++ 0 0·97 0·83
Cardioembolic ischaemic stroke
rs4284256 1:157675273 Intergenic FCRL3 1 T 0·18 1·41
(1·22–1·64)
3·13 × 10–6 -+++++ 66·5 0·01 0·96
rs12646447 4:111699326 Intergenic PITX2 102 C 0·12 1·53
(1·31–1·80)
1·92 × 10–7 ++++++ 0 0·44 0·99
rs72184 5:123754837 Intergenic ZNF608 1 G 0·43 1·30
(1·17–1·46)
2·29 × 10–6 +++++++++ 9·1 0·6 0·90
rs72794386 5:127479278 Intronic SLC12A2 22 T 0·10 1·67
(1·39–2·00)
4·37 × 10–8 +++++ 0 0·87 0·97
rs1428155 5:151281633 Intronic GLRA1 2 C 0·38 1·28
(1·16–1·43)
3·10 × 10–6 +++++++++ 36·2 0·13 1·00
rs7771564 6:22504092 Intergenic HDGFL1 4 G 0·10 1·53
(1·28–1·82)
2·10 × 10–6 ++++++ 0 0·67 0·99
rs1495081 8:15314955 Intergenic TUSC3 1 C 0·14 1·48
(1·25–1·74)
3·09 × 10–6 ++-+++ 49·9 0·08 0·88
rs2393938 10:44063812 UTR5 ZNF239 1 C 0·12 1·45
(1·24–1·70)
3·47 × 10–6 ++++++ 0 0·51 0·99
rs11021485 11:95968208 Intronic MAML2 1 A 0·12 1·60
(1·32–1·94)
1·24 × 10–6 +++++ 30·5 0·22 0·82
rs710009 14:59184500 Intergenic DACT1 4 G 0·16 1·41
(1·22–1·64)
3·62 × 10–6 +++++++ 0 0·84 0·98
Non-cardioembolic ischaemic stroke
rs77744591 13:81142325 Intergenic SPRY2 1 T 0·08 1·34
(1·18–1·51)
3·44 × 10–6 +++++-+ 0 0·97 0·93
Only associations with the lead single nucleotide polymorphism in each locus are shown, and full set of genetic associations at p<5×10–6 is presented in the appendix (pp 48–54). All results are presented with 
respect to the minor allele as coded allele. UTR57 *Chromosome positions with respect to National Center for Biotechnology Information Build 37 data. †Number of variants reaching p<5×10–6 in the locus. 
‡p value after genomic control. §Direction refers to direction of eﬀ ect size with respect to the minor allele in each study contributing to the meta-analysis (in alphabetic order), “+” sign refers to positive values of 
betas and “-” sign referes to  negative values of betas with respect to the minor allele. ¶Heterogeneity (I2) ranges between 0 and 100, with higher values suggesting more heterogeneity. ||p value for heterogeneity 
was calculated with the Cochran’s Q test. **Mean value of imputation quality across studies. 
Table 2: Single nucleotide polymorphism associated with risk of stroke at p<5 × 10–6
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Gene Discovery Validation Combined total
CHARGE SiGN METASTROKE HVH1 CADISP Validation 
meta-analysis
Meta-analysis
Hazard 
ratio 
(95% CI)
p value Odds 
ratio 
(95% CI)
p value Odds 
ratio 
(95% CI)
p value Odds 
ratio 
(95% CI)
p value Odds 
ratio 
(95% CI)
p value Odds 
ratio 
(95% CI)
p value Odds 
ratio 
(95% CI)
p value
All stroke*
rs6433905 UBE2E3 1·21
(1·12–
1·31)
2·54 × 10–6 1·02
(0·97–
1·08)
0·41 1·11
(0·98–
1·27)
0·11 1·09
(0·83–
1·44)
0·54 0·72
(0·54–
0·95)
0·018 1·03
(0·98–
1·07)
0·22 1·07
(1·03–
1·12)
8·72 × 10–4
rs12204590† FOXF2 1·14
(1·08–
1·20)
2·17 × 10–6 1·07
(1·03–
1·11)
1·02 × 10–3 1·07
(0·98–
1·16)
0·13 1·03
(0·86–
1·24)
0·73 1·08
(0·92–
1·26)
0·36 1·06
(1·03–
1·09)
2·15 × 10–4 1·08
(1·05–
1·12)
1·48 × 10–8
rs790919 OPRM1 1·12
(1·07–
1·17)
2·44 × 10–6 1·00
(0·97–
1·03)
0·88 1·01
(0·95–
1·09)
0·70 0·88
(0·76–
1·02)
0·10 1·06
(0·93–
1·21)
0·37 1·00
(0·98–
1·03)
0·80 1·03
(1·01–
1·05)
0·013
rs11788316 FLJ41200 1·13
(1·07–
1·19)
2·49 × 10–6 0·99
(0·96–
1·03)
0·73 1·07
(0·99–
1·16)
0·074 1·01
(0·84–
1·21)
0·93 0·99
(0·85–
1·15)
0·89 1·01
(0·99–
1·04)
0·38 1·03
(1·01–
1·06)
7·53 × 10–3
rs11627959 CFL2 0·89
(0·85–
0·93)
2·23 × 10–6 0·99
(0·96–
1·02)
0·70 1·00
(0·93–
1·08)
0·93 1·00
(0·85–
1·17)
0·96 1·03
(0·90–
1·18)
0·62 1·01
(0·98–
1·03)
0·53 0·97
(0·95–
0·99)
0·011
rs4899120 SYNE2 1·19
(1·11–
1·29)
4·71 × 10–6 1·02
(0·97–
1·07)
0·50 1·00
(0·88–
1·14)
0·98 1·05
(0·80–
1·37)
0·73 1·16
(0·92–
1·46)
0·21 1·02
(0·99–
1·07)
0·23 1·06
(1·02–
1·10)
2·00 × 10–3
Ischaemic stroke‡
rs62262077 ALCAM 1·17
(1·10–
1·24)
6·04 × 10–7 0·99
(0·96–
1·02)
0·52 1·03
(0·95–
1·12)
0·46 1·03
(0·84–
1·26)
0·78 1·02
(0·88–
1·18)
0·82 1·01
(0·98–
1·03)
0·63 1·03
(1·01–
1·06)
0·015
rs10037362 CDH6 1·27
(1·15–
1·40)
4·41 × 10–6 0·98
(0·93–
1·03)
0·40 0·99
(0·87–
1·12)
0·84 0·93
(0·69–
1·26)
0·65 0·86
(0·66–
1·13)
0·27 0·97
(0·93–
1·02)
0·22 1·01
(0·97–
1·05)
0·55
rs4448595 NEBL-
AS1
0·83
(0·77–
0·90)
2·50 × 10–6 1·01
(0·97–
1·05)
0·72 1·02
(0·93–
1·12)
0·69 0·89
(0·72–
1·10)
0·28 0·96
(0·81–
1·14)
0·65 1·00
(0·97–
1·03)
0·97 0·98
(0·95–
1·00)
0·09
rs11833579 NINJ2 1·19
(1·12–
1·27)
5·74 × 10–8 0·98
(0·95–
1·01)
0·21 0·96
(0·88–
1·04)
0·28 1·04
(0·85–
1·29)
0·69 0·96
(0·82–
1·12)
0·57 0·98
(0·95–
1·01)
0·14 1·01
(0·98–
1·03)
0·47
rs77858481 SPRY2 1·38
(1·22–
1·55)
2·32 × 10–7 0·99
(0·93–
1·06)
0·75 0·90
(0·77–
1·05)
0·17 1·02
(0·72–
1·44)
0·93 0·91
(0·69–
1·20)
0·48 0·98
(0·93–
1·03)
0·50 1·03
(0·99–
1·08)
0·17
Cardioembolic ischaemic stroke§
rs4284256 FCRL3 1·41
(1·22–
1·64)
3·13 × 10–6 0·96
(0·90–
1·04)
0·31 0·93
(0·78–
1·12)
0·45 1·03
(0·69–
1·55)
0·88 0·98
(0·75–
1·28)
0·90 0·96
(0·90–
1·01)
0·13 1·02
(0·97–
1·09)
0·41
rs12646447† PITX2 1·53
(1·31–
1·80)
1·92 × 10–7 1·39
(1·29–
1·50)
3·15 × 10–18 1·17
(0·98–
1·41)
0·083 1·62
(1·09–
2·42)
0·018 1·04
(0·78–
1·37)
0·80 1·36
(1·28–
1·44)
1·89 × 10–23 1·37
(1·29–
1·46)
4·72 × 10–24
rs72184 ZNF608 1·30
(1·17–
1·46)
2·29 × 10–6 1·02
(0·96–
1·08)
0·53 0·99
(0·87–
1·13)
0·90 0·92
(0·67–
1·28)
0·63 1·03
(0·85–
1·26)
0·74 1·02
(0·97–
1·06)
0·49 1·06
(1·01–
1·10)
0·017
rs72794386 SLC12A2 1·67
(1·39–
2·00)
4·37 × 10–8 0·97
(0·89–
1·06)
0·51 1·09
(0·87–
1·37)
0·46 0·95
(0·56–
1·62)
0·85 0·78
(0·54–
1·14)
0·18 0·96
(0·90–
1·03)
0·27 1·06
(0·99–
1·14)
0·12
rs1428155 GLRA1 1·28
(1·16–
1·43)
3·10 × 10–6 0·97
(0·92–
1·03)
0·33 0·95
(0·83–
1·08)
0·44 0·90
(0·66–
1·24)
0·51 0·99
(0·81–
1·21)
0·94 0·99
(0·95–
1·03)
0·64 1·02
(0·98–
1·07)
0·38
rs7771564 HDGFL1 1·53
(1·28–
1·82)
2·10 × 10–6 1·01
(0·92–
1·10)
0·87 0·88
(0·70–
1·10)
0·25 1·23
(0·77–
1·96)
0·39 1·20
(0·89–
1·62)
0·24 1·00
(0·93–
1·07)
0·97 1·08
(1·01–
1·17)
0·031
(Table 3 continues on next page)
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In the cross-sectional validation samples (19 816 stroke 
patients vs 50 988 control participants), associations for 
two loci were replicated at p<2·38 × 10–³ signiﬁ cance and 
reached genome-wide signiﬁ cance (p<5 × 10–⁸) in the 
combined analysis (table 3). The ﬁ rst association we 
found was a previously unreported locus (chr6p25·3, 
lead SNP rs12204590), located between FOXQ1 and 
FOXF2, showing association with risk of incident all-
stroke (combined odds ratio [OR] 1·08 95% CI 
1·05–1·12, p=1·48 × 10–⁸; MAF 21%; ﬁ gure 1). 
Associations in each study are shown in the appendix (p 
38). The second locus (chr4q25, near PITX2) is a known 
risk locus for cardioembolic ischaemic stroke (combined 
OR 1·37, 1·29–1·46, p=4·72 × 10–²⁴ for incident 
cardioembolic ischaemic stroke; MAF 12%). The 
SLC12A2 locus (genome-wide signiﬁ cant in the small 
cardioembolic ischaemic stroke discovery sample) did 
not show evidence of replication (p=0·27).
We also explored association of the chr6p25·3 locus 
with stroke subtypes. In the discovery sample, lead SNP 
rs12204590 was associated with incident ischaemic 
stroke (HR 1·13, 95% CI 1·06–1·20), p=1·64 × 10–⁴; 
non-cardioembolic ischaemic stroke: HR 1·12, 1·04–1·22, 
p=4·35 × 10–³; and cardioembolic ischaemic stroke: 
HR 1·10 0·95–1·27, p=0·21). In validation samples, we 
detected an association with small-vessel ischaemic 
stroke (OR 1·08, 95% CI 1·02–1·14, p=0·0094) for 
rs12200309 (in complete linkage disequilibrium with 
rs12204590), using TOAST subtypes, whereas association 
with large-vessel and cardioembolic ischaemic stroke was 
not signiﬁ cant (p>0·35). The association with small-vessel 
ischaemic stroke was also evident when using 
CCS-causative subtyping where available (SiGN; OR 1·11, 
1·05–1·18, p=0·00029; appendix p 55). chromosome 
6p25·3 was also signiﬁ cantly associated with increasing 
burden of white matter hyperintensity in the general 
population (most signiﬁ cant p value was p=0·0025, 
appendix p 56). The HR for association of rs12204590 
with incident fatal ischaemic stroke (n=271; HR 1·21, 
0·99–1·50, p=0·0684) was higher than with non-fatal 
ischaemic stroke (n=2300; HR 1·14, 1·06–1·22, 
p=4·93 × 10–⁴), but the diﬀ erence was not signiﬁ cant 
(appendix pp 57–59). We did not record any heterogeneity 
by ethnicity for associations between the chr6p25 locus 
and stroke risk (appendix p 60). 
The genomic region where the variant associated with 
increased stroke risk and adjacent linked variants (linkage 
disequilibrium r²>0·50) are located seems to include 
enhancers (regions of DNA that activate transcription of 
nearby genes). This genomic region also includes DNase I 
hypersensitive regions, a marker of open chromatin 
associated with active cis-regulatory elements important 
Gene Discovery Validation Combined total
CHARGE SiGN METASTROKE HVH1 CADISP Validation 
meta-analysis
Meta-analysis
Hazard 
ratio 
(95% CI)
p value Odds 
ratio 
(95% CI)
p value Odds 
ratio 
(95% CI)
p value Odds 
ratio 
(95% CI)
p value Odds 
ratio 
(95% CI)
p value Odds 
ratio 
(95% CI)
p value Odds 
ratio 
(95% CI)
p value
(Continued from previous page)
rs1495081 TUSC3 1·48
(1·25–
1·74)
3·09 × 10–6 1·05
(0·98–
1·14)
0·18 0·89
(0·72–
1·09)
0·25 1·35
(0·84–
2·16)
0·21 1·05
(0·79–
1·40)
0·73 1·04
(0·98–
1·10)
0·24 1·10
(1·03–
1·17)
5·07 × 10–3
rs2393938 ZNF239 1·45
(1·24–
1·70)
3·47 × 10–6 1·02
(0·94–
1·10)
0·68 1·01
(0·84–
1·22)
0·88 0·95
(0·60–
1·52)
0·84 0·96
(0·71–
1·29)
0·76 1·00
(0·94–
1·07)
0·95 1·07
(1·01–
1·15)
0·029
rs11021485 MAML2 1·60
(1·32–
1·94)
1·24 × 10–6 0·94
(0·86–
1·03)
0·17 0·77
(0·63–
0·95)
0·015 0·51
(0·25–
1·04)
0·063 1·06
(0·78–
1·43)
0·73 0·92
(0·86–
0·99)
0·017 0·99
(0·92–
1·07)
0·82
rs710009 DACT1 1·41
(1·22–
1·64)
3·62 × 10–6 1·00
(0·92–
1·07)
0·93 0·96
(0·80–
1·15)
0·68 1·21
(0·80–
1·83)
0·37 1·10
(0·84–
1·43)
0·50 1·00
(0·94–
1·06)
0·96 1·06
(1·00–
1·13)
0·048
Non-cardioembolic ischaemic stroke¶
rs77744591 SPRY2 1·34
(1·18–
1·51)
3·44 × 10–6 1·08
(0·96–
1·21)
0·19 1·08
(0·84–
1·40)
0·53 1·39
(0·74–
2·59)
0·30 0·91
(0·47–
1·77)
0·78 1·08
(0·99–
1·18)
0·80 1·18
(1·09–
1·28)
3·22 × 10–5
rs77744591 SPRY2 1·34
(1·18–
1·51)
3·44 × 10–6 1·12
(1·02–
1·24)
0·023 1·06
(0·80–
1·40)
0·68 0·83
(0·52–
1·31)
0·42 0·73
(0·24–
2·22)
0·56 1·11
(1·02–
1·20)
0·16 1·18
(1·10–
1·27)
1·08 × 10–5
*Validationresults from association analyses of ischaemic stroke for SiGN, METASTROKE, and CADISP, and of all stroke for HVH1. †Loci that reach genome-wide signiﬁ cance (p<5 × 10–8) in the combined 
meta-analysis. ‡Follow-up results from association analyses of ischaemic stroke for SiGN, METASTROKE, HVH1, and CADISP. §Validation results from association analyses of cardioembolic ischaemic stroke for 
SiGN, METASTROKE, HVH1, and CADISP (TOAST subtyping). ¶Validation results from association analyses of large-vessel ischaemic stroke (ﬁ rst line) and small-vessel ischaemic stroke (second line) for SiGN, 
METASTROKE, HVH1, and CADISP (TOAST subtyping).  
Table 3: Validation of top loci in independent cross-sectional case-control studies associated with risk of stroke
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Figure 1: Regional association plot of rs12204590 in discovery stage
Association of rs12204590 and other genotyped or imputed SNPs (circles) in the region with incident all-stroke. Colour variation shows linkage disequilibrium 
between SNPs (r2) as calculated in 1000 Genomes Project (phase 1, version 3). Blue lines show estimated recombination rates. Coloured tracks seen at bottom of 
ﬁ gure were added using the University of California, Santa Cruz genome browser and the RegulomeDB database. SNP track=SNPs encompassing the selected region 
and red dashed line shows position of top SNP (rs12204590). Regulome track=RegulomeDB scores and variants with lower scores have higher probability of acting as 
regulatory variants. DNase track=DNase hypersensitive regions assayed in 125 cell types (ENCODE project, Release 3, 2014). TFbs track=regions where transcription 
factors, proteins responsible for modulating gene transcription, bind to DNA as assayed by ChIP-seq assay (ENCODE project, Release 3, 2013).
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Figure 2: Cerebrovascular phenotype of FOXF2 and FOXC1 deletions in humans and FoxF2 knockout mice, and expression of foxf2a and foxf2b in zebraﬁ sh 
(A–D) In two patients with segmental deletion encompassing FOXC1, white matter hyperintensities are noted in periventricular region (A,B) and subcortical regions (B). 
In two patients with segmental deletion of both FOXC1 and FOXF2 (C,D), mean white matter hyperintensities volume is increased by more than ten times (E), 
in subcortical and periventricular regions (see appendix p 68 for white matter hyperintensities volumes in each of the four patients). (F–I) Cerebral cortex of conditional 
Foxf2 knockout mouse showing ischaemic infarction and haemorrhagic tissue. (F) Area with condensed eosinophilic cytoplasm and pyknotic nuclei (to the right dashed 
line) that indicates recent ischaemic infarction. (Fi) Normal tissue and (Fii) tissue with ischaemic infarction at higher magniﬁ cation. (G) Glial ﬁ brillary acidic protein 
immunoﬂ uorescence of area with reactive astrogliosis in cerebral cortex of Foxf2 conditional knockout mouse. (H) Cerebral cortex from control mouse showing normal 
neuronal tissue and intact capillaries. (I) Haemorrhagic area of cerebral cortex from Foxf2 conditional knockout mouse. Extravascular erythrocytes seen both as intact 
cells (homogeneous greenish blue) and lysed cells (black). (J–M) RNA in situ hybridisation (purple) of larval zebraﬁ sh brains shows expression of foxf2a (J) and foxf2b (K) 
in presumptive pericytes compared with known pericyte markers pdgfrβ (L) and notch3 (M; purple) around capillaries in 1-month old larval zebraﬁ sh (brown). 
(N-Q) foxf2–/– mutants have reduced expression of pericyte marker pdgfrβ in 4-day postfertilisation embryonic cerebral vasculature. (R–U) Loss of foxf2b results in 
reduction of the smooth-muscle marker acta2:GFP coverage of blood vessels in wild type (n=11), foxf2+/– (n=31), and Foxf2–/– (n=20) embryonic cerebral vasculature. 
(R–T) Examples of high, medium, and low branch order coverage scored from 0 to the 4th order branch in vessel coverage presented as percentages of total embryo 
counts (U). Arrow heads in images J–Q refer to positions showing pericytes. 
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for transcription of nearby genes (ﬁ gure 1, appendix 
pp 61, 62). Two SNPs (rs7750826 and rs2006798, r²>0·75 
with rs12204590) had RegulomeDB scores of 2b, 
suggesting a probable role in regulating gene expression 
(combination of transcription factor binding site and 
DNase peak and footprint; ﬁ gure 1, appendix pp 63, 64). 
The genomic region that includes the lead variant and 
variants in linkage disequilibrium also includes two 
protein-coding genes, FOXQ1 and FOXF2. The same 
region also includes a microRNA (MIR6720). However, if 
we expand the regional plot to a 1 Mb region around the 
lead variant, the region also includes two other protein 
coding genes (FOXC1 and GMDS) and a long non-coding 
RNA (LINC01622; ﬁ gure 1). We did an extensive search of 
publicaly available expression quantitative trait loci 
(eQTL)16 and miRNA databases,17 examined mRNA 
expression of FOXF2 and adjacent genes in the 
dorsolateral prefrontal cortex of 508 participants enrolled 
in the Religious Orders Study and the Rush Memory and 
Aging Project,18 and mined large sets of epigenomic data 
from the International Human Epigenome Consortium 
(appendix pp 65–67). eQTL or methylation quantitative 
trait loci in this region were absent except for a long non-
coding RNA (LOC285768) in the human brain 
(p=5·25 × 10–⁷ for rs7746700, average in ten brain regions 
in the BRAINEAC database). However, the diﬀ erent 
distribution of histone modiﬁ cations associated with 
active genes in cells expressing FOXF2 or FOXQ1 
suggested that these variants are likely to lie within the 
regulatory region of FOXF2 (appendix pp 39, 40). 
Moreover, we noted the lowest CpG methylation levels 
(indicating highest activity) at this locus in the fetal brain 
compared with any other tissue.19
We have previously described that patients with 
Axenfeld-Rieger syndrome, a rare heterogeneous 
condition with maldevelopment of the ocular anterior 
segment attributable to mutation or copy number 
variation of FOXC1 (adjacent to FOXF2 on chr6p25), 
have increased burden of MRI markers of cerebral 
small vessel disease.20 Within this cohort of people 
with FOXC1-attributable Axenfeld-Rieger syndrome, we 
identiﬁ ed two patients with 300 kb segmental deletions 
encompassing both FOXC1 and FOXF2 and found that 
they had extensive, conﬂ uent white matter hyperintensity, 
with more than ten-times larger volume of white matter 
hyperintensity than two patients with segmental 
deletions of FOXC1 only (30 kb), although the small 
number of patients does not allow a formal statistical 
comparison to be made. All patients were younger than 
35 years (range 2–32 years) and lacked vascular risk 
factors (ﬁ gure 2A–E, appendix p 68). White matter 
hyperintensities are normally absent or negligible in this 
age range in the general population.21
To understand the mechanism at the tissue level we 
used histology of the brains from six mice 6 weeks after 
Foxf2 inactivation and found areas of neurons 
with pyknotic nuclei and eosinophilic cytoplasm 
(ﬁ gure 2F–Fii), suggestive of ischaemic infarction, in ﬁ ve 
of the brains. Patches with elevated levels of glial ﬁ brillary 
acidic protein in astrocytes (ﬁ gure 2G) indicated reactive 
gliosis. Increased magniﬁ cation revealed a few instances 
of microhaemorrhage with extravascular erythrocytes 
(ﬁ gure 2I). By contrast, brains from control mice 
contained only occasional and scattered neurons that 
showed signs of apoptosis or isolated astrocytes with 
increased glial ﬁ brillary acidic protein immuonoreactivity 
and no visible haemorrhagic lesions (ﬁ gure 2H). Mice in 
which Foxf2 had been deleted had signiﬁ cantly higher 
mortality than control mice. Usually the animals were 
found dead, but some had to be euthanised after showing 
behaviour indicative of brain damage, such as circling or 
lopsided gait.
In zebraﬁ sh, foxf2a and foxf2b (FOXF2 orthologs) are 
expressed in the cerebral endothelium in pericytes, 
similar to expression in pericytes in mice (ﬁ gure 2J,K). 
Expression occurrs in a pattern similar to those of 
established pericyte markers pdgfrβ and notch3 
(ﬁ gure 2L,M). We made two zebraﬁ sh knockout 
lines, foxf2bca22 and foxf2bca23, with nonsense mutations in 
the ﬁ rst exon of foxf2b that would result in a translation 
block before the essential DNA-binding domain 
(appendix p 35). Both alleles had identical phenotypes. 
foxf2b mutants had decreased expression of the brain 
pericyte marker pdgfrβ (ﬁ gure 2N–Q), which is indicative 
of pericyte maturation defects and decreased acta2-
positive smooth muscle cell coverage on large cerebral 
vessels, which in turn is suggestive of smooth-muscle 
defects (ﬁ gure 2R–U, appendix p 41). In homozygous 
mutants, acta2 was visible up to second order of cerebral 
vessel branching or less versus fourth or higher order 
branch in wild-type or heterozygous embryos. 
When considering risk loci for ischaemic stroke reported 
by previous cross-sectional studies,2 we found that seven 
of the eight published loci were associated with incident 
stroke in the discovery stage of the present population-
based GWAS, predominantly in the same subtype as the 
original study (p value range=0·047–7·82 × 10–⁵, appendix 
p 69). One known risk locus for ischaemic stroke (PITX2) 
also showed association with incident intracerebral 
haemorrhage (p=0·0031), and one known risk locus for 
intracerebral haemorrhage (PMF1-BGLAP), also a known 
risk locus for increasing white matter hyperintensity 
burden,12 was associated with incident ischaemic stroke 
(p=0·00064), both in the same direction (appendix p 31).
Discussion
In a large population-based GWAS meta-analysis of 
incident stroke, with validation in the largest available 
cross-sectional stroke GWAS, we identiﬁ ed a novel 
genome-wide signiﬁ cant association of common variants 
in the chr6p25·3 region, near FOXF2, with risk of stroke. 
Associations predominated with small-vessel ischaemic 
stroke, and signiﬁ cant association was noted with burden 
of white matter hyperintensity; in addition, patients with 
For the International Human 
Epigenome Consortium see 
www.ihec.org
For the BRAINEAC database see 
http://www.braineac.org/
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rare segmental deletions of FOXF2 also showed extensive 
burden of white matter hyperintensity. These ﬁ ndings 
suggest an eﬀ ect of this locus on cerebral small vessel 
disease; however, the mechanism by which this 
transcription factor results in cerebral small vessel 
disease and stroke is unclear. To investigate the possibility 
of a role of FOXF2 in stroke, we did experimental studies 
in two animal species to examine its role in cerebral 
vessel development and stability. We showed areas of 
infarction and microhaemorrhages in brains of 
conditional Foxf2 mutant mice. We showed in zebraﬁ sh 
that foxf2b was expressed in brain pericytes (as in mice14) 
and that reduction in foxf2b function led to diﬀ erentiation 
defects of both pericytes and smooth muscle cells in the 
developing cerebral vasculature.
Converging evidence from the present study and 
previous publications suggests an important role of 
FOXF2 in cerebrovascular disease. In mice, we 
previously showed that Foxf2 is required for brain 
pericyte diﬀ erentiation and blood–brain barrier 
development, with Foxf2–/– embryos showing thickened 
endothelium, perivascular oedema, thinning of the 
vascular basal lamina, and a leaky blood–brain barrier.14 
We had also described that Foxf2 inactivation in adult 
mice results in endothelial thickening and blood–brain 
barrier breakdown,14 an important mediator of cerebral 
small vessel disease, and increased mortality.22 In the 
conditional Foxf2 mutant, we analysed mice brains 
6 weeks after Foxf2 inactivation and we found signs of 
brain infarction, with reactive astrogliosis and 
microhaemorrhages. Of note in previous experiments, 
Foxf2–/– mouse embryos developed intracranial 
haemorrhage,14 whereas areas of microhaemorrhage 
were scarce in conditional Foxf2 mutant brains. We 
were also unable to show an association of the chr6p25.3 
locus with intracerebral haemorrhage in the largest 
available collaborative genetic association study, 
although power might have been limited by the size of 
the study (appendix p 70). In zebraﬁ sh, foxf2b knockout 
led to disruption of cerebral vasculature with decreased 
pericyte density and smooth muscle cell coverage 
(ﬁ gure 2). Foxf2 is ﬁ rst expressed in the neural crest and 
in mice regulates pathways involved in mural cell 
(pericyte and vascular smooth muscle cell) 
diﬀ erentiation, including the pdgfβ and serum response 
factor pathways.14,23 We did not see haemorrhage in the 
zebraﬁ sh foxf2 mutant model during embryonic stages. 
We note that we knocked out only one of two foxf2 genes 
in zebraﬁ sh, and even though mural cell markers have 
changed expression in foxf2b mutants, there might be 
genetic compensation from the foxf2a gene that could 
make the phenotype less severe. However, we have not 
found expression changes of foxf2a in zebraﬁ sh having 
mutant foxf2b. We cannot exclude haemorrhage 
occurring at juvenile or adult stages that we have not 
been able to examine. In summary, our data suggest 
that association of FOXF2 and stroke might arise from 
diﬀ erentiation defects of cerebral vascular mural cells. 
To demonstrate the cellular requirement for Foxf2 by 
expression under a vascular mural cell promoter for 
prevention of stroke and mural cell phenotypes in 
mutants is an important future experiment, but is 
beyond the scope of this study. 
Forkhead transcription factors are involved in various 
developmental and biological processes, and tend to be 
distributed in clusters on the genome.24,25 The 
evolutionarily conserved chr6p25 cluster comprises 
FOXQ1, FOXF2, and FOXC1. Our lead stroke risk variants 
lie between FOXQ1 (22·4 kb) and FOXF2 (52·7 kb). By 
contrast with the compelling experimental evidence for a 
central role of FOXF2 in cerebrovascular disease, FOXQ1 
has not been implicated in cerebrovascular phenotypes; 
mutant mice for this gene show mainly altered hair 
diﬀ erentiation and gastric mucin secretion.26,27 The third 
gene in the cluster, FOXC1 (225 kb downstream of FOXF2 
and 273·3 kb downstream of stroke risk variants), is also 
expressed in the brain vasculature and inﬂ uences vessel 
morphogenesis28 and arteriovenous speciﬁ cation.29 MRI 
analysis of patients with FOXC1-attributable Axenfeld-
Rieger syndrome revealed MRI features of cerebral small 
vessel disease (including increased burden of white 
matter hyper intensity), and genetic variants downstream 
of FOXC1 were associated with burden of white matter 
hyper intensity in the general population.20 These 
previously described variants are independent (r²<0·017) 
from the stroke risk variants near FOXF2 described 
here.20,30 These ﬁ ndings, together with the ten-times 
increased burden of white matter hyper intensity in 
patients with segmental deletion of both FOXC1 and 
FOXF2 versus FOXC1 alone, suggest an independent role 
of FOXF2 in cerebral small vessel disease. Diﬀ erences in 
the roles of foxf2 and foxc1a and foxc1b are also seen in the 
zebraﬁ sh model.31 Knockdown of zebraﬁ sh foxc1a/b leads 
to embryonic cerebral hemorrhage in embryos,31 whereas 
knockout of foxf2b at the same developmental stage does 
not. Thus, although the two genes are closely related, 
there are indications that their roles in vascular mural 
cells might be distinct.
Intriguingly, PITX2 (chr4q25), a known risk locus for 
cardioembolic ischaemic stroke and atrial ﬁ brillation32,33 
as well as being genome-wide signiﬁ cant for 
cardioembolic ischaemic stroke in the present sample, 
encodes a neural crest–expressed transcription factor 
that physically interacts with FOXC1 and harbours 
causal mutations for Axenfeld-Rieger syndrome.20 
Variants near PITX2 were associated with burden of 
white matter hyperintensity.20,30 In this study, common 
variants near PITX2 were also associated with risk of 
intracerebral haemorrhage, of which the main 
mechanism in the general population is small vessel 
disease.34 These ﬁ ndings suggest that FOXF2, FOXC1, 
and PITX2 could perhaps contribute to cerebrovascular 
disease via partly shared pathways,  of relevance in 
cerebral small arteries.
Articles
706 www.thelancet.com/neurology   Vol 15   June 2016
The small number of incident strokes (n=4300), 
particularly stroke subtypes (n=602 for cardioembolic 
ischaemic stroke, whereas small-vessel occlusion, 
large-vessel ischaemic stroke, and other stroke subtypes 
had to be merged into a single category) might have 
hampered our ability to detect additional associations. 
The study was also underpowered (<80% power) to 
detect associations with eﬀ ect sizes smaller than OR 1·10 
and allele frequency lower than 5% (appendix p 34). 
Although the results of the described animal studies 
suggest that FOXF2 is the causal gene underlying the 
observed genetic association with stroke and small 
vessel disease at chr6p25, functional annotation of the 
identiﬁ ed risk variants is limited, with an absence of 
eQTL despite an extensive search of publicly available 
and other databases, possibly reﬂ ecting tissue speciﬁ city 
or primarily developmental eﬀ ects. These eﬀ ects are 
supported by a higher expression of FOXF2 in fetal brain 
than adult brain, and lower methylation levels of the 
stroke risk locus in fetal tissues than adult tissues. 
Another limitation is that we only explored common 
variants and not rare variants in this region. In addition, 
we have used an additive genetic model only, which is 
the most powerful approach when the underlying 
genetic model is unknown, but we cannot exclude that 
associations with genetic risk loci following a recessive 
or dominant model might have been missed. 
Nevertheless, we conﬁ rmed and extended the range of 
associations for previously discovered stroke risk loci in 
a population-based sample. For the ﬁ rst time, to our 
knowledge, we describe shared genetic variation 
underlying both ischaemic stroke (chr4q25) and 
intracerebral haemorrhage (chr1q22), in agreement with 
some monogenic strokes having both ischaemic and 
haemorrhagic phenotypes, mostly with underlying small 
vessel disease.35–37 The association we previously 
described between chr12p13 and incident stroke in a 
smaller, overlapping sample was also the most 
signiﬁ cant association with ischaemic stroke in the 
present population-based GWAS,5 showing a stronger 
association with incident fatal stroke versus non-fatal 
stroke, which suggests an eﬀ ect on stroke survival 
(appendix pp 58, 59). 
In summary, we identiﬁ ed common variants near 
FOXF2 associated with increased stroke susceptibility 
(especially of the small vessel subtype) and extensive 
subclinical small vessel disease. This association is 
particularly interesting because GWAS have not yet 
discovered risk loci for small-vessel ischaemic stroke 
(except for an association with the PRKCH locus 
identiﬁ ed in a  study of Japanese participants, which was 
not found in European populations).6,38 Brain imaging 
data from patients with rare segmental deletions 
encompassing FOXF2, and functional experiments 
across evolutionarily separated species, suggest an 
important role of FOXF2 in cerebrovascular disease—
especially cerebral small vessel disease—possibly by 
aﬀ ecting diﬀ erentiation of cerebral vascular mural cells. 
Cerebral small vessel disease is a major, but poorly 
understood, cause of stroke in all ethnic groups, and 
subclinical small vessel disease has been associated with 
progressive functional and cognitive decline and 
increased risk of dementia. At present, no mechanism-
based treatment for small vessel disease is available, 
other than management of vascular risk factors. Our 
ﬁ ndings provide promising grounds for follow-up, 
pointing to a possible mechanism of stroke and small 
vessel disease. Further research is warranted to explore 
whether these ﬁ ndings can have implications for clinical 
practice.
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